Allergan PLC. (AGN) Given New $277.00 Price Target at Royal Bank Of Canada
Allergan PLC. (NYSE:AGN) had its price target decreased by investment analysts at Royal Bank Of Canada from $285.00 to $277.00 in a report released on Monday. The brokerage presently has an “outperform” rating on the stock. Royal Bank Of Canada’s price objective indicates a potential upside of 35.35% from the stock’s previous close.
Several other equities research analysts have also recently commented on AGN. Cowen and Company set a $400.00 price target on shares of Allergan PLC. and gave the stock a “buy” rating in a research report on Thursday, June 8th. Citigroup Inc. reiterated a “buy” rating and issued a $280.00 price target on shares of Allergan PLC. in a report on Wednesday, September 20th. Mizuho reduced their price target on shares of Allergan PLC. from $275.00 to $267.00 and set a “buy” rating for the company in a report on Friday, June 9th. Cantor Fitzgerald initiated coverage on shares of Allergan PLC. in a report on Friday, June 16th. They issued a “neutral” rating and a $231.00 price target for the company. Finally, Zacks Investment Research upgraded shares of Allergan PLC. from a “hold” rating to a “buy” rating and set a $270.00 price target for the company in a report on Tuesday, July 11th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and fourteen have issued a buy rating to the company’s stock. Allergan PLC. has a consensus rating of “Buy” and a consensus price target of $272.94.
Shares of Allergan PLC. (AGN) opened at 204.65 on Monday. The company has a market cap of $68.42 billion, a price-to-earnings ratio of 6.24 and a beta of 1.18. Allergan PLC. has a 12 month low of $184.50 and a 12 month high of $256.80. The stock has a 50 day moving average of $229.79 and a 200-day moving average of $236.07.
Allergan PLC. (NYSE:AGN) last announced its earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.95 by $0.07. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The company had revenue of $4.01 billion during the quarter, compared to the consensus estimate of $3.95 billion. During the same period in the previous year, the firm posted $3.35 earnings per share. The company’s revenue was up 8.8% on a year-over-year basis. On average, analysts forecast that Allergan PLC. will post $16.26 EPS for the current year.
Several hedge funds and other institutional investors have recently modified their holdings of AGN. Howard Hughes Medical Institute purchased a new stake in Allergan PLC. in the second quarter worth approximately $103,000. Jacobi Capital Management LLC lifted its position in Allergan PLC. by 4.9% in the first quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock valued at $112,000 after purchasing an additional 22 shares during the last quarter. JNBA Financial Advisors lifted its position in Allergan PLC. by 2.5% in the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock valued at $116,000 after purchasing an additional 12 shares during the last quarter. Massey Quick & Co. LLC lifted its position in Allergan PLC. by 334.8% in the second quarter. Massey Quick & Co. LLC now owns 500 shares of the company’s stock valued at $122,000 after purchasing an additional 385 shares during the last quarter. Finally, Pacific Center for Financial Services lifted its position in Allergan PLC. by 805.1% in the first quarter. Pacific Center for Financial Services now owns 534 shares of the company’s stock valued at $128,000 after purchasing an additional 475 shares during the last quarter. 82.02% of the stock is owned by institutional investors.
About Allergan PLC.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.